Podcasts about gw pharma

Hunter Land, PhD is the Vice President of Research & Development at Biopharmaceutical Research Company, one of the few DEA Schedule I, FDA compliant cannabinoid research and development companies. He has 20 years of R&D expertise across 25 different indications, as well as 12 years of cannabinoid-focused research.  Most notably, he was GW Pharma's first full-time R&D employee in the US, where he played a critical role in the development of Epidiolex® and Sativex®, and co-authored multiple protocols for the treatment of refractory epilepsy, multiple sclerosis, and pain. At CannMed 23, Hunter's presentation was titled Effect of Cannabinoids and Cannflavins on Neurodegeneration, Lifespan, and Healthspan, which is the basis for our conversation today. You can find a link to that video in the show description. Topics we discussed include: Defining lifespan, healthspan, and longevity Why C. elegans are good organisms for studying toxicity and longevity Whe entourage effect, more specifically whether a combination of compounds has a greater effect on longevity than single compounds How do cannabis compounds compare to other longevity drugs like metformin and resveratrol Whether cannabis compounds could be used prophylactically for conditions like Alzheimer's and dementiaDetermining the ideal dosing range for cannabinoids Whether CBD and CBG should be incorporated into a healthy lifestyle to improve longevity  Thanks to This Episode's Sponsor - Trulieve Trulieve strives to bring you the relief you need in a product you can trust. Their plants are hand-grown in a facility with a controlled environment specially designed to reduce unwanted chemicals and pests, keeping the process as natural as possible at every turn. Their mission is to provide compassionate care patients can trust when traditional medicine is not enough. Their specially-trained staff works hand-in-hand with YOUR physician to provide the right products and the correct dosage to ensure you get the compassionate care you need. To learn more visit trulieve.com Additional Resources Effect of Cannabinoids and Cannflavins on Neurodegeneration, Lifespan, and Healthspan - Hunter Land (CannMed 23 Presentation Video) Biopharmaceutical Research CompanyReview the Podcast!CannMed ArchiveCannMed Community Board [Facebook Group]

In this episode, we are joined by Dr. Lutz Harms. Lutz is a Senior Director at GW Pharma Germany and has over 20 years of experience in leading orphan drug and specialty businesses in Germany and Europe. He has a proven track record in delivering growth and performance turnarounds. With over 15 years of experience in leadership of orphan drug and specialist medicines businesses in Germany including market access (AMNOG process) and launches/relaunches. Topics: 1. Orphan Drug Trials 2. Launching Epidyolex 3. Market Access Requirements * Twitter - @TheCannabisRev2 * LinkedIn - @thecannabisreview * Episode Library - https://www.thecannabisreview.ie

The role of genetics in both pediatric and adult epilepsies is expanding. Now, making a genetic diagnosis in epilepsy isn't just important for family planning and prognostication - these diagnoses can also improve patients' care starting at the moment of diagnosis. Our guest today, Ingrid Scheffer, is a leader in gene discovery in epilepsy. Dr. Scheffer is a Laureate Professor of Pediatric Neurology at the University of Melbourne, and she directs the Children's Epilepsy Research Center at Austin Health. She says while there's still a long way to go before precision medicine is available for the hundreds of known genetic epilepsies, her patients are already benefiting from genetic testing, in many ways. Dr. Scheffer was interviewed by ANA Investigates Producer and epileptologist Dr. Rohit Das of UT Southwestern Medical Center. Series 3, Episode 12. Featuring: Guest: Ingrid Scheffer, AO FRS FAA FAHMS, University of Melbourne Interviewer/Producer: Rohit Das, MD, UT Southwestern Disclosures: In the past 24 months, Ingrid Scheffer has consulted for Atheneum Partners, Biohaven Pharmaceuticals Inc, Care Beyond Diagnosis, Epilepsy Consortium and Zynerba Pharmaceuticals, has served as an investigator for Anavex Life Sciences, Cerebral Therapeutics, Cerecin Inc, Cereval Therapeutics, Eisai, Encoded Therapeutics, EpiMinder Inc, Epygenyx, ES-Therapeutics, GW Pharma, Marinus, Neurocrine BioSciences, Ovid Therapeutics, Takeda Pharmaceuticals, UCB, Ultragenyx, Xenon Pharmaceutical, Zogenix and Zynerba; received speaker honoraria from Biocodex, BioMarin, Chiesi, Liva Nova and UCB; received funding for travel from Biomarin, Eisai and UCB; and served on scientific advisory boards for Bellberry Ltd, BioMarin, Chiesi, Eisai, Encoded Therapeutics, Knopp Biosciences, Rogcon, Takeda Pharmaceuticals and UCB. Ingrid Scheffer may accrue future revenue on pending patent WO2009/086591: Diagnostic And Therapeutic Methods For EFMR (Epilepsy And Mental Retardation Limited To Females); has a patent for SCN1A testing held by Bionomics Inc and licensed to various diagnostic companies (WO/2006/133508); she has a patent for a molecular diagnostic/therapeutic target for benign familial infantile epilepsy (BFIE) [PRRT2] WO/2013/059884 with royalties paid.

Celadon Pharmaceuticals founder and chief executive James Short tells Proactive that the group is the first medicinal cannabinoid company to list in the UK since GW Pharma. The regulatory framework for the UK market is different now from when GW Pharma floated, he explains, which means it can generate revenue as well as go down the road of clinical trials. People have said to Short that the company has a first-mover advantage, and the potential scale of the market is incredible and I "genuinely want other ‘Celadons' in the UK as well", he adds.

On this week's episode, we're joined by Professor Mike Barnes, Neurologist, Director of Maple Tree Consultancy, and Chairman of The Medical Cannabis Clinicians SocietyWe explore the future of Medical Cannabis in the UK by investigating current prescribing practices, stakeholder challenges, and how the government can help develop the industry.→ View full show notes, summary, and access resources here: https://www.canverse.global/shownotes/e135About Professor Mike BarnesProfessor Mike Barnes is a neurologist and cannabis physician. He has worked in cannabis for 20 years, initially with GW Pharma on the first cannabis medicine - Sativex. He oversaw the first UK cannabis prescription for the child Alfie Dingley in 2018 and, after the law change in November 2018, then launched the Medical Cannabis Clinicians Society in November 2018 which now has over 250 clinical members. In 2021 he launched the Cannabis Industry Council with over 100 members across the sector. He runs a medical cannabis consultancy with Hannah Deacon who is the UK's best-known campaigner and mother of Alfie Dingley. He is the Clinical Director of the T21 project.Quotables‘[Cannabis'] medical history is actually more prominent and more robust… than its recreational history' 09:36‘It's down to education. And I think it's Tony Blair that said, education, education, education. And that's the same with cannabis. It's absolutely essential to educate the doctors first, educate politicians after say second, but it's mainly the conservatism of medical professionals holding it back now' 27:45ResourcesThe Medical Cannabis Clinicians Society Website: https://www.ukmccs.org/Professor Barnes' LinkedIn: https://www.linkedin.com/in/michael-barnes-6048b223/Maple Tree Consultants LinkedIn: https://www.linkedin.com/in/michael-barnes-6048b223/#Cannabis Industry Council Website: https://cannabisindustrycouncil.org/Professor Mike Barnes' Website: https://www.profmichaelbarnes.co.uk/

Episode 27 of the Farms Not Pharms podcast finds burntmd interviewing cannabis activist, attorney, and entrepreneur Don E. Wirtshafter. Don is one of the original founders of GW Pharmaceuticals, founded the Ohio Hempery in 1990, and currently curates The Cannabis Museum, which you can check out at CannabisMuseum.com.

Bright Minds Biosciences Inc (CNSX:DRUG, OTCMKTS:BMBIF) is a biotech company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Our viewers may be familiar with GW Pharmaceuticals PLC (formerly NASDAQ:GWPH), recently acquired by Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), and its Epidiolex® (CBD) oral solution as a treatment for childhood-onset epilepsy. Bright Mind’s focus is on […]

This week on The Green Rush, our hosts Nick and Anne are chatting with David Johnson, CEO of Enveric Biosciences, a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients.  It’s been a while since the Green Rush team has talked about CBD so we used this opportunity to get an update on the state of the space including how CBD is fitting into the existing medical landscape, the ways that technology is progressing the validation of these molecules and what the market could look like in the next several years. We also explore Enveric’s business model and how they compare to other players in the industry as well as key news from the industry including Jazz Pharmaceuticals acquisition of GW Pharma.  Now on to our conversation with David Johnson of Enveric Biosciences. David Johnson, Chairman and CEO of Enveric Biosciences Former CEO of Convatec, oversaw the $4.1B spin out of Convatec from Bristol Myers Squibb; former CEO of Alliqua Biomedical, a developer of wound care technologies. Links and mentions in the show https://www.enveric.com/ Diverse Biotech PartnershipPureForm Partnership Links to the guest’s company and social media accounts David Johnson’s LinkedIn: https://www.linkedin.com/in/david-johnson-235b0224/  Show Credits: This episode was hosted by Anne Donohoe and Nick Opich of KCSA Strategic Communications.  Special thanks to our Program Director Shea Gunther. You can learn more about how KCSA Cannabis can help your cannabiz by visiting www.kcsa-cannabis.com or emailing greenrush@kcsa.com. You can also connect with us via our social channels: Twitter: @The_GreenRush  Instagram: @thegreenrush_podcast LinkedIn: https://www.linkedin.com/company/thegreenrushpodcast/  Facebook: https://www.facebook.com/TheGreenRushPodcast/  YouTube: https://www.youtube.com/channel/UCuEQkvdjpUnPyhF59wxseqw?disable_polymer=true

How will the GW pharma deal affect the industry?This week we welcome back Oliver Zugel, CEO and Founder of Foliumed - international producers of pharmaceutical grade cannabis and extracts in Columbia. Together, we explore the recent acquisition of GW Pharma by Jazz Pharmaceuticals, how CBD, medical cannabis, and pharmaceutical cannabis will differentiate themselves from each other, and how this will impact the cannabis industry going forwards.→ View full show notes, summary, and access resources here: https://www.canverse.global/shownotes/e101About OliverOliver Zugel is the founder and CEO of Foliumed, a medical cannabis producer with operations  in Germany and Colombia. Foliumed focuses on non-smokable, pharmaceutical product forms which permit precise dosing. Its ingredients are sourced from its organic farm in the Colombian highlands, and processed in a German EU-GMP certified facility. Quotables2021 is the year columbian product will become more well known within the major medical cannabis marketplace 03:00GW is ‘quite a big fish to swallow' for the Irish company 05:00Medical cannabis companies operate in a very different business model than GW' 07:35The time has come for medical cannabis companies to start thinking about how they compete 09:55‘The medical cannabis industry isn't about curing cancer. It's about improving the life and wellbeing of an ageing population' 12:30ResourcesFollow Oliver on LinkedIn: https://www.linkedin.com/in/oliverzugel/Foliumed's Website: www.foliumed.comEPISODE #76 Standardisation and Medical Cannabis with Oliver Zugel, CEO at Foliume‪d‬ :https://podcasts.apple.com/gb/podcast/episode-76-standardisation-medical-cannabis-oliver/id1454098889?i=1000489119600

After you smash the notification bell, since our information is time sensitive, you'll want to share this episode to all of your socials including IG story. In this episode you'll learn what to when your stock goes to the moon! Because profits aren't yours until you ring the register. Vettz and G-Money have a little bit of a brag session on the news that Jazz Pharma (yes that's a real company) decided to buyout GW Pharmaceuticals sending GWPH stock soaring 50% and bagging G-Money the coolest $9K ever. This was discussed in depth on what GW does in episode 11 as a pharmaceutical grade cannabis company developing drugs for diseases in multiple sclerosis among others. Listen in to find out what G-Money is gonna do next! Buy, Sell, Hold? A mix of all three? Listen in! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

GW Pharmaceuticals, creators of the first patented cannabinoid drug Epidiolex, is to be acquired by global pharmaceutical firm Jazz Pharmaceutical. Valuing the acquisition at a little over $7 billion US dollars, the move has been seen as a big splash by many in the

60 Seconds you need to know before you go Jon Najarian here in Park City enjoy and love in this note, take a look at Jazz Pharmaceutical because they're buying GW Pharma that has GW shares up 46% it's also driving Tilray TLRY which we add unusual activity and, and APHA as well. Google up 7% on blowout earnings numbers, I've got Kos headphones, you know Portnoy's favorite. This is up 30% again today, Capri holdings, which is Michael Kors, and so forth blowout quarter they're up 7% Spotify down 7% because even though the high end product that they sell is up 24% and streamers are up to 155 million, it's still not enough. also taken a look at SMG Scott's Miracle Grow. First Quarter profit first ever first quarter profit and that stock moving higher by about 3% Curevac. This is a German vaccine company. They're partnering with GSK for future vaccines. I am Jon Najarian. I'll have three three for you 3pm Eastern today.

Carl Quintanilla, Jim Cramer and David Faber took an in-depth look at the future for Amazon after Jeff Bezos announced he is stepping down as CEO of the company. Amazon Web Services chief Andy Jassy has been chosen to succeed him in the top job. Bezos will become executive chairman. Carl, Jim and David also discussed blowout earnings from Amazon and Google parent Alphabet. GameStop and the Reddit-fueled frenzy remain in the spotlight: Treasury Secretary Yellen plans to meet with top financial regulators this week, and the anchors reacted to what the CEO of Reddit told Kara Swisher during a New York Times podcast. Also in focus: More earnings winners and losers -- plus M&A news, with Jazz Pharmaceuticals agreeing to buy GW Pharma for $7.2-billion in cash and stock.

Today on After Hours: - Jazz Pharma will acquire GW Pharma - pot stocks popped. - eBay and PayPal tick all-time highs after hours. - Spotify struggled after earnings. - The SEC will review the short squeeze. ___This podcast reflects only the opinions of the hosts and is intended for informational purposes only. It is not intended to serve as a recommendation to buy or sell any security either in a self-directed ST Invest LLC account or any other account, and is not an offer or sale of a security. The podcast is not a research report and is not intended to serve as the basis for any investment decision. Before making decisions with legal, tax, or accounting ramifications, you should consult appropriate professionals and/or investment adviser for advice that is specific to your situation. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. All third party information provided in this podcast is not intended to serve as the basis for any investment decision and does not reflect the views of ST Invest LLC, StockTwits, Inc., or any of their subsidiaries or affiliates. Third party information referenced in this podcast has been obtained from sources that are generally deemed to be reliable, but their accuracy and completeness cannot be guaranteed. Therefore, Stocktwits, Inc., and its affiliates and subsidiaries assume no responsibility or liability for any errors or omissions in the content of the podcast. The use of or reference to third-party information in this podcast shall not be construed as an endorsement by or affiliation with the third-party information providers or their services. This podcast should not be copied, distributed, published or reproduced, in whole or in part. If you have any comments or questions, please contact rrosenberger@stocktwits.com

We discuss the Aphria-Tilray merger, Sundial's takeover of Zenabis and the AYR-LHS acquisition. We move on to talk about changes in the lending landscape since legalization, Canopy suing GW Pharma and the OCS reducing skus + new craft category.

Canadian cannabis producer Canopy Growth is suing Britain's GW Pharmaceuticals in U.S. federal court. The U.S. patent was issued to Canopy the same day the lawsuit was filed, alleging that GW is knowingly infringing upon Canopy's intellectual property. GW allegedly uses a Canopy-patented method to extract CBD, the active ingredient in its Epidiolex medication. After obtaining a ruling in Canopy's favor, they would be in a strong position to claim further patent infringement, including against almost every major cannabis-oil manufacturer in the United States. Anyone using a CO2 extraction method would then be using technology owned by Canopy Growth and would owe them money, inclduing 87% of GW Pharma's revenue that came from U.S. CBD sales. Show Notes: Cannabis firm Canopy Growth sues GW Pharma, claiming patent infringement https://mjbizdaily.com/daily-news/#cannabis-firm-canopy-growth-sues-gw-pharma-claiming-patent-infringement Guest: Katrina Glogowski, Seattle Attorney & Angel Investor https://www.linkedin.com/in/katrina-glogowski-711a985/ Host: Josh Kincaid, Capital Markets Analyst & host of your cannabis business podcast. https://www.linkedin.com/in/joshkincaid/ Episode 614 of The Talking Hedge: Your Cannabis Business Podcast. ​Covering cannabis products, reviews, business news, interviews, investments, events, and more. https://www.theTalkingHedgepodcast.com Music Info: Song: Dark Trap Beats Hard Rap Instrumental | Gang | 2018Artist: LuxrayBeats Keywords: Hemp News, Weed News, Cannabis News, Marijuana News, Cannabis Business, Marijuana Business, Cannabis Industry News, Marijuana Industry News, Weed News 420, Talking Hedge Podcast, Cannabis Podcast, Marijuana Podcast, Business Podcast, CBD podcast, THC podcast, Cannabis Pitch Deck, Marijuana Pitch Deck, Marijuana Investment Deck, Cannabis Investment Deck, Cannabis Compliance, Cannabis Data, Cannabis Banking, Cannabis Investment, Pot Stocks, Cannabis Stocks, Weed Stocks, Marijuana Stocks, Cannabis Data, Marijuana Data, Cannabis Analytics, Marijuana Analytics, Cannabis Sales Data, Marijuana Sales Data Josh is not an investment adviser. The Talking Hedge is long gold and silver. Listeners should always speak to their personal financial advisers.

Canadian cannabis producer Canopy Growth is suing Britain’s GW Pharmaceuticals in U.S. federal court. The U.S. patent was issued to Canopy the same day the lawsuit was filed, alleging that GW is knowingly infringing upon Canopy’s intellectual property. GW allegedly uses a Canopy-patented method to extract CBD, the active ingredient in its Epidiolex medication. After obtaining a ruling in Canopy's favor, they would be in a strong position to claim further patent infringement, including against almost every major cannabis-oil manufacturer in the United States. Anyone using a CO2 extraction method would then be using technology owned by Canopy Growth and would owe them money, inclduing 87% of GW Pharma’s revenue that came from U.S. CBD sales. Show Notes: Cannabis firm Canopy Growth sues GW Pharma, claiming patent infringement https://mjbizdaily.com/daily-news/#cannabis-firm-canopy-growth-sues-gw-pharma-claiming-patent-infringement Guest: Katrina Glogowski, Seattle Attorney & Angel Investor https://www.linkedin.com/in/katrina-glogowski-711a985/ Host: Josh Kincaid, Capital Markets Analyst & host of your cannabis business podcast. https://www.linkedin.com/in/joshkincaid/ Episode 614 of The Talking Hedge: Your Cannabis Business Podcast. ​Covering cannabis products, reviews, business news, interviews, investments, events, and more. https://www.theTalkingHedgepodcast.com Music Info: Song: Dark Trap Beats Hard Rap Instrumental | Gang | 2018Artist: LuxrayBeats Keywords: Hemp News, Weed News, Cannabis News, Marijuana News, Cannabis Business, Marijuana Business, Cannabis Industry News, Marijuana Industry News, Weed News 420, Talking Hedge Podcast, Cannabis Podcast, Marijuana Podcast, Business Podcast, CBD podcast, THC podcast, Cannabis Pitch Deck, Marijuana Pitch Deck, Marijuana Investment Deck, Cannabis Investment Deck, Cannabis Compliance, Cannabis Data, Cannabis Banking, Cannabis Investment, Pot Stocks, Cannabis Stocks, Weed Stocks, Marijuana Stocks, Cannabis Data, Marijuana Data, Cannabis Analytics, Marijuana Analytics, Cannabis Sales Data, Marijuana Sales Data Josh is not an investment adviser. The Talking Hedge is long gold and silver. Listeners should always speak to their personal financial advisers.

Canadian cannabis producer Canopy Growth is suing Britain’s GW Pharmaceuticals in U.S. federal court. The U.S. patent was issued to Canopy the same day the lawsuit was filed, alleging that GW is knowingly infringing upon Canopy’s intellectual property. GW allegedly uses a Canopy-patented method to extract CBD, the active ingredient in its Epidiolex medication. After obtaining a ruling in Canopy's favor, they would be in a strong position to claim further patent infringement, including against almost every major cannabis-oil manufacturer in the United States. Anyone using a CO2 extraction method would then be using technology owned by Canopy Growth and would owe them money, inclduing 87% of GW Pharma’s revenue that came from U.S. CBD sales. Show Notes: Cannabis firm Canopy Growth sues GW Pharma, claiming patent infringement https://mjbizdaily.com/daily-news/#cannabis-firm-canopy-growth-sues-gw-pharma-claiming-patent-infringement Guest: Katrina Glogowski, Seattle Attorney & Angel Investor https://www.linkedin.com/in/katrina-glogowski-711a985/ Host: Josh Kincaid, Capital Markets Analyst & host of your cannabis business podcast. https://www.linkedin.com/in/joshkincaid/ Episode 614 of The Talking Hedge: Your Cannabis Business Podcast. ​Covering cannabis products, reviews, business news, interviews, investments, events, and more. https://www.theTalkingHedgepodcast.com Music Info: Song: Dark Trap Beats Hard Rap Instrumental | Gang | 2018Artist: LuxrayBeats Keywords: Hemp News, Weed News, Cannabis News, Marijuana News, Cannabis Business, Marijuana Business, Cannabis Industry News, Marijuana Industry News, Weed News 420, Talking Hedge Podcast, Cannabis Podcast, Marijuana Podcast, Business Podcast, CBD podcast, THC podcast, Cannabis Pitch Deck, Marijuana Pitch Deck, Marijuana Investment Deck, Cannabis Investment Deck, Cannabis Compliance, Cannabis Data, Cannabis Banking, Cannabis Investment, Pot Stocks, Cannabis Stocks, Weed Stocks, Marijuana Stocks, Cannabis Data, Marijuana Data, Cannabis Analytics, Marijuana Analytics, Cannabis Sales Data, Marijuana Sales Data Josh is not an investment adviser. The Talking Hedge is long gold and silver. Listeners should always speak to their personal financial advisers. --- Support this podcast: https://anchor.fm/talkinghedge/support

Check out this week’s episode of the podcast – we had a great time chatting with Emily Paxhia, Co-Founder & Managing Partner of Poseidon Asset Management, one of the longest running funds in the cannabis industry. As early investors in household names in cannabis, such as PAX, Aphria and GW Pharma (to name a few!), Emily gave us a huge amount of insight into how they find the next big companies to invest in, their due diligence processes and how international investment decisions and regulatory monitoring intersect.

This week we're joined by Will Muecke, Co-founder and Managing Member at Artemis Growth Partners - ESG and impact-oriented private equity platform dedicated to investing in the worldwide cannabis industry.Join us as we discuss the recent acquisition of Bridge Farm Group, what impact investing is, and why now is a great time to invest in cannabis.This episode is sponsored by Central European Cannabis Forum who are holding an online virtual conference on the 9th and 10th June 2020 on the topic of Medical Cannabis in Central and Eastern Europe. If you are interested in attending, you can grab a 20% discount on your tickets via this link: http://cecf.eu/CCEpisode Summary Environmental, Social, and Governance (ESG) refers to the three central factors in measuring the sustainability and societal impact of an investment in a company or business. These types of investments try to ‘do a little bit more than just profit' by making the world a better place through investment.Will had a traditional career in investment banking and finance, working at Goldman Sachs for a number of years within Healthcare Services, and later on founding a private equity group named CoreCo Private Equity which manages investment funds that promote sustainable business development, support social impact investment opportunities, and create outsized investor returns through growth equity investments in the emerging markets.In 2017, he founded Artemis Growth Partners, Impact investors within the global cannabis industry. The team consist of a team of professional investors, operators, and advisors who have built and run successful, award-winning domestic and international impact funds.Artemis Growth Partners currently have over $200m of assets under management, and continually raise capital as a single purpose vehicle. They manage 6 funds which range in size.Will's interest in cannabis came from his sister's use of medical cannabis during cancer treatment - she was able to alleviate opioid side effects through its use. Artemis Growth Partners' investments within the space focus on health and wellness, social justice, regenerative forming and exiting the opioid crisis.UK Cannabis horticulture company Bridge Farm, has recently been acquired by Artemis Growth Partners for £66m. The farm has 2million square feet of cultivation space and is the leading producer of ornamental plant, flowers and herbs in the UK.Bridge Farm hold one of 12 Research and Development licenses in the UK, alongside GW Pharma, which over time may evolve into a commercial license allowing the production of high THC buds.The firm also have investments in Orium Group - Europe's first independent extraction company, and a contract manufacturing company who have operating assets within the Czech Republic.Artemis Growth Partners' take a multimodal approach to their investments across the health and wellness categories and have adopted a pharma based model in the UK in comparison to the CPG (Consumer packaged goods) model in the USA.Cannabis is a disruptor for almost every industry - the paper industry, textiles and clothing, and even plastics can use the cannabis plant to create new sustainable materials in each of these sectors.Will hopes that what is referred to ‘impact investing' now, will just be called ‘business' in the future.Quotables‘The investable category of cannabis is only growing' 28:14‘The industry is growing at a rate of 20-25% per year' 28:40ResourcesArtemis Growth Partners Website: https://www.artemisgrowth.com/Join Will on LinkedIn: https://www.linkedin.com/in/wmuecke/Join Artemis Growth on Twitter: 

Professor Manuel Guzman is Professor of Molecular Biology at the Complutense University in Madrid where he has been a leading light in discovering the anticancer properties of cannabinoids such as THC and CBD. He led the team behind the first ever clinical trial for THC as an antitumoral agent in the rare type of brain cancer, glioblastoma. I recorded this interview for an article for Project CBD examining just how close we are to the approval of a cannabis-based anticancer drug, but managed to draw Manuel into a whole host of fascinating topics, on which he talked openly and frankly. Highlights include: A summary of how near or far we are away from a cannabis-based cancer drug.How the bar is set higher for cannabinoids compared to other areas of research.What other types of cancer are likely to move onto the clinical studies stage in cannabinoid research.Manuel's view on GW Pharma's 'mining' of the cannabis field with patents for different types of cannabinoid combinations and diseases. Why a cannabis-based cancer drug will always be trialled alongside standard treatments such as chemo or radiotherapy.Practical advice from Manuel for patients with cancer about how to safely use cannabis oil. The biphasic effect of THC and how this may influence its antitumoral activity.An explanation of the difference between tolerability and tolerance.A call to action to patients to play their part in the normalisation of cannabis by telling their doctors about their cannabis use. Transcript:For space reasons, I cannot include the full transcript here, but feel free to contact me via my website marybiles.com and I will happily send it. Support the show (https://www.paypal.com/paypalme/marybiles71)

Go to inmygrow.com to SUBSCRIBE to the show or find us on the Stitcher app. Email us at inmygrow@gmail.com Find us on Instagram @inmygrow  Click here to go to 101cbd.org Go to DeltaLeafLabs.com to order your “Plant DNA Sex Testing Kits” Click Here for the Amazon link to help support the show. Show Notes:  Welcome back to the show, I hope Thanksgiving was awesome.  Later I'm going to talk about how we a 0.3% THC in hemp. I tried to boost an IG post and it was rejected, why do they send out the invite?  Do you think the President will beat his rival with legalized marijuana? It rained most of the holiday weekend. I set up a twitter account, I don't know how to use it, not sure how active i'll be over there.   Strain of the Week:   Cherry AK-47- This sativa-dominant strain mixes Colombian, Mexican, Thai, and Afghani varieties,  is a rare cherry phenotype of AK-47. With its reddish-purple characteristics and cherry aroma. It gives me a steady, long-lasting cerebral high that kept me mentally, focused and super chatty. While its scent is sour, earthy sweet flowers that you can taste.       Side Note: Rolled a couple of holiday joints w/ it and others and as I was cleaning what I broke up I found a seed at the bottom of the tray.  I don't know which flower it came from since it was a mix of Lava Cake, Cherry AK-47 and Pineapple Kush.   Social Media  I'm going to start a new segment called “Free the Plant” and it's going to mostly focus on hemp and CBD.  I have to admit I don't think I know enough about both of these. I've been focused on the cannabis / THC side of things that I wasn't paying attention to what's going on over there.  I didn't notice GW Pharma patented CBD. Both of these markets are really new and moving really fast.   Psychoactive vs. Intoxication Report from the cannabis front line DUI in neighboring cannabis states https://www.marijuanamoment.net/alcohol-related-car-crashes-declined-in-idaho-after-washington-legalized-marijuana-next-door/ Anthony Clark smokes a joint on camera https://www.marijuanamoment.net/congressional-candidate-smokes-marijuana-and-talks-legalization-in-campaign-video/  All joking aside we need to regulate better in California https://www.cnn.com/2019/11/26/business/california-cannabis-industry-layoffs/index.html  I Want to talk about:  How did we get this 0.3% THC limit on hemp -Interview with Dr. Ernest Smalls  http://www.internationalhempassociation.org/jiha/jiha6208.html  -Le Dain Commission Interim Report  https://www.ukcia.org/research/cunion/cu60.htm  -Recommended methods for the identification and analysis of cannabis and cannabis products  https://www.unodc.org/documents/scientific/ST-NAR-40-Ebook_1.pdf  -2018 Farm Bill  https://republicans-agriculture.house.gov/uploadedfiles/2018_farm_bill_conference_report_text.pdf  Support the show - Go to Patreon.com and find the In My Grow Show and donate what you can. “In My Grow Show - Grow Learn Teach” T-shirts are here for you.  to check it out.  CLICK HERE check it out.  Music: Silent Partner - Butchers

This Week In Marijuana Business News for the week ended Nov. 15, 2019, with host Nick Thomas. Headlines include: Massachusetts keeps cannabis vape ban, orders quarantine of products as regulators focus on suspect additive Two more California cannabis companies disclose layoffs Canopy’s net revenue plunges as challenges pile up in Canadian cannabis sector Cresco Labs, Origin House revamp cannabis merger as value falls more than 50% and close delayed Michigan Marijuana Transfers New UK guidelines recommend public insurance coverage for two GW Pharma cannabis medicines, plus a synthetic cannabinoid Cross-pollination drives growing disputes between marijuana, hemp farmers Subscribe to both of our podcasts on Apple, Stitcher and here on our site!

This episode of the podcast is brought to you by our sponsor, CBD MD. For some of the best broad spectrum CBD (read here if you don't know what that means: https://www.cbdschool.com/what-is-broad-spectrum-cbd/) at the best prices, visit CBD MD: https://www.cbdschool.com/cbd-md Use code cbdschool for 20% OFF your order! Show Notes: Jahan is back! If you don't know already, Jahan Marcu is one of my favorite researchers and authorities in the whole cannabis space. It's always fascinating to have him on and that's why this episode is extra long. Enjoy! Check out all the links to the references we talked about. My first episode with Jahan Marcu: https://soundcloud.com/cbd-school/jahan-marcu-cbd-school-podcast-9 Connect with Jahan: email: jmarcu@irccmh.org Twitter: @jahanmarcu INTERNATIONAL RESEARCH CENTER ON CANNABIS AND MENTAL HEALTH: https://irccmh.org/ References: Athletes for CARE: https://www.athletesforcare.org/ HOW SAFE IS YOUR VAPE PEN?: https://www.projectcbd.org/about/safety-and-quality-control/how-safe-your-vape-pen Labeling Accuracy of Cannabidiol Extracts Sold Online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818782/ Roger Adams: https://en.wikipedia.org/wiki/Roger_Adams Isaac Newton May Have Died from Eating Mercury: https://unrealfacts.com/isaac-newton-may-died-eating-mercury/ Navigator Genomics Cannabinoid Drug Interaction Testing: https://navigatorgenomics.com/ GW Pharma: https://www.gwpharm.com/ Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy: https://www.ncbi.nlm.nih.gov/pubmed/25843054 Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data: https://www.ncbi.nlm.nih.gov/pubmed/26362106 Raphael Mechoulam: https://en.wikipedia.org/wiki/Raphael_Mechoulam

1. Featured Article: Practice guideline update summary: Efficacy and tolerability of new antiepileptic drugs I: Treatment of new-onset epilepsy2. Lesson of the Week: Functional Disorders This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 10, 2018 issue of Neurology. In the first segment, Dr. Derek Bauer talks with Dr. Jacqueline French about her paper, a summary of a recent practice guideline on the treatment of new-onset epilepsy. In the second part of the podcast, Dr. David Lapides continues the Lesson of the Week discussion on functional disorders with Dr. Jon Stone. DISCLOSURES: Dr. French has served on scientific advisory boards and consulted for the Epilepsy Foundation, Acadia, Acorda, Adamas, Alexza, Anavex, Axcella Health, Biogen, BioPharm Solutions, Cavion, Cerecor, Cerebral Therapeutics, Concert Pharmaceuticals, Covance, CuroNZ, Eisai, Empatica, Engage, Georgia Regents University, Glaxo Smith-Kline, GW Pharma, J&J Pharmaceuticals, Marinus, MonosolRx, Monteris, Nestle-Health Science, Neurelis, Novartis, Otsuka, Ovid, Pfizer, Pfizer-Neusentis, Sage Therapeutics, Shire, SK Life Sciences, Sunovion, Takeda, UCB Inc., Upsher Smith, Ultragenyx, Xenon Pharmaceuticals, Xeris, Zogenix and Zynerba; has received research support from Alexza, Acorda, LCGH, Eisai Medical Research, LCGH, Lundbeck, Neurelis, Pfizer, SK life sciences, Sunovion, Takeda, UCB, Upsher-Smith, Biogen, NINDS (2U01NS038455-11A1), Epilepsy Foundation, and Epilepsy Study Consortium; has received paid travel to present findings at scientific meetings, present at investigators' meetings, attend advisory boards, or give lectures from Epilepsy Study Consortium, Epilepsy Foundation, International League Against Epilepsy, American Academy of Neurology, American Epilepsy Foundation, Adamas, Biogen, Eisai, Engage, GW Pharma, GSK, Novartis, Otsuka, Ovid, Pfizer, Sage, Sunovion, Takeda, UCB, Ultragenyx, Upsher-Smith, Zynerba, Blackfynn Pfizer, Pfizer-Neusentis, Sage, SK Life Sciences, Sunovion, Takeda, UCB Inc., Upsher Smith,Zogenix, and Zynerba; serves on editorial boards for Lancet Neurology, Neurology Today, and Epilepsy Currents; and serves as President, Epilepsy Study Consortium Chief Scientific Officer, Epilepsy Foundation. Drs. Bauer and Lapides report no disclosures. Dr. Stone receives publishing royalties from UptoDate; runs a free self-help website for patients with functional disorders www.neurosymptoms.org; and carries out regular expert witness work in relation to personal injury and medical negligence.

Promo: GW Pharmaceuticals scores a big thumbs up from a panel of FDA experts for its marijuana-based drug. Plus, Biogen pays a $1 billion dollars for expanded access to Ionis’ novel pipeline.

Organifi Quah! In this episode of Quah, sponsored by Organifi (organifi.com, code "mindpump" for 20% off), Sal, Adam & Justin answer Pump Head questions about how to “outgrow” people gracefully, how many times per week females should hit each muscle group, the role that food sensitivities play in the inability to lose fat and how to define failure. Sal-stradamus…he may be predicting the future. (4:50) Snapchat on the decline…Did a post by Kylie Jenner spark a massive loss in users? (7:10) DoorDash on the rise…Uber the new ambulance? The guys talk all things tech. (11:00) There is a community for anyone these days. Find out what Eproctophilia is. (16:22) If the guys were a furry, who would they be? Find out! (19:09) Weight Watchers to shift focus from weight loss to wellness. More big companies reading the market change? The guys give their thoughts. (22:18) Four Sigmatic Kombucha?? Maybe the weirdest commercial to date. (28:00) Cannabis Drug Could Extend Lives of Brain Cancer Patients. Cannabis discussion amongst the guys. (33:50) Trump making more silly moves to halt our economy? Political talk with Mind Pump. (39:32) Thrive Market Unboxing Segment – Bone Broth Edition (50:25) Quah question #1 – Do you have any tips to outgrow people gracefully? (52:50) Quah question #2 – How many times should a female, not male, work each muscle group per week? (1:07:18) Quah question #3 – Do you think food sensitivities play a large role in your inability to lose fat? (1:13:48) Quah question #4 – How do you define failure? (1:21:54) Links/Products Mentioned: Hit Makers: The Science of Popularity in an Age of Distraction – Book by Derek Thompson Vero - True Social Snapchat's Value Drops $1.3 Billion After 1 Kylie Jenner Tweet DoorDash is raising $535 million from SoftBank and others at a $1.4 billion valuation Urban Dictionary: fart fetish Weight Watchers is shifting from weight loss to wellness as ‘healthy is the new skinny' Four Sigmatic ** Use the discount code “mindpump” for 15% off of your first order of health & energy boosting mushroom products.** GW Pharma's cannabis-derived combo med helps brain cancer patients Cannabis and Cannabinoids - National Cancer Institute Trump's ‘Smart' Tariffs Don't Make Economic Sense Thrive Market One FREE month's membership $20 off your first three purchases of $49 or more (That's $60 off total!) Free shipping on orders of $49 or more Continuous Glucose Monitoring Ep 715-Mind Pump Goes Deep with Ben Pakulski People Mentioned: Tom Bilyeu (@TomBilyeu)  Twitter Donald J. Trump (@realDonaldTrump)  Twitter Barack Obama (@BarackObama)  Twitter Tom DeLonge (@tomdelonge)  Twitter Ben Pakulski (@ifbbbenpak)  Instagram Also check out Thrive Market! Thrive Market makes purchasing organic, non-GMO affordable. With prices up to 50% off retail, Thrive Market blows away most conventional, non-organic foods. PLUS, they offer a NO RISK way to get started which includes: 1. One FREE month's membership 2. $20 Off your first three purchases of $49 or more (That's $60 off total!) 3. Free shipping on orders of $49 or more How can you go wrong with this offer? To take advantage of this offer go to www.thrivemarket.com/mindpump You insure your car but do you insure YOU? If you don't, and you are the primary breadwinner, you will likely leave your loved ones facing hardship and struggle if you die (harsh reality). Perhaps you think life insurance is expensive, but if you are fit and healthy, you can qualify for approved rates that are truly inexpensive and affordable. To find out if you qualify for the best rates in the industry, go get a quote at www.HealthIQ.com/mindpump Would you like to be coached by Sal, Adam & Justin? You can get 30 days of virtual coaching from them for FREE at www.mindpumpmedia.com. Get our newest program, MAPS Prime Pro, which shows you how to self assess and correct muscle recruitment patterns that cause pain and impede performance and gains. Get it at www.mindpumpmedia.com! Get MAPS Prime, MAPS Anywhere, MAPS Anabolic, MAPS Performance, MAPS Aesthetic, the Butt Builder Blueprint, the Sexy Athlete Mod AND KB4A (The MAPS Super Bundle) packaged together at a substantial DISCOUNT at www.mindpumpmedia.com. Make EVERY workout better with MAPS Prime, the only pre-workout you need… it is now available at mindpumpmedia.com Have Sal, Adam & Justin personally train you via video instruction on our YouTube channel, Mind Pump TV. Be sure to Subscribe for updates. Get your Kimera Koffee at www.kimerakoffee.com, code "mindpump" for 10% off! Get Organifi, certified organic greens, protein, probiotics, etc at www.organifi.com Use the code “mindpump” for 20% off. Go to foursigmatic.com/mindpump and use the discount code “mindpump” for 15% off of your first order of health & energy boosting mushroom products. Add to the incredible brain enhancing effect of Kimera Koffee with www.brain.fm/mindpump 10 Free sessions! Music for the brain for incredible focus, sleep and naps! Also includes 20% if you purchase! Please subscribe, rate and review this show! Each week our favorite reviewers are announced on the show and sent Mind Pump T-shirts! Have questions for Mind Pump? Each Monday on Instagram (@mindpumpmedia) look for the QUAH post and input your question there. (Sal, Adam & Justin will answer as many questions as they can)

Episode 7 invites Doug Fine to the lair and we discuss many projects that Doug is currently involved in including Hawaii hemp research, a project with the Colville indian tribe in Washington State, hemp in hemp from Vermont, hemp legislation in New Mexico, the Central US Hemp Growers Conference in Wisconsin next week, and a few things on the horizon for 2018. We also recap a little more on the CBD raids in Tennessee that happened last week entitled Operation Candy Crush/CBD Gummy Bears along with what's going on with the GW Pharma bill making rounds and ruffling feathers around the Colorado capital.     Learn more about this episode of Let's Talk Hemp at www.letstalkhemp.com. Got questions for future episodes? Email us at the422@letstalkhemp.com. LTH422 intro and outro music powered by MoTron and the #HempCaster Guitar @ Hole in the Sky Music.

Episode 6 of #LetsTalkHemp and #The422 has us discussing GW Pharma and new legislation being proposed in Colorado and possible scenarios of how the cannabinoid markets will develop for natural products/nutraceuticals, pharmaceutical/medical, and recreational cannabis.  This weeks guests include lobbyist and political consultant Cindy Sovine from Sovine Consulting, and Tim Gordon, president of the Colorado Hemp Industries Association and CEO of Functional Remedies and CBDRx.  We'll also be discussing Operation CBD Gummy Bear(AKA Operation Candy Crush) in Tennessee along with America's obsession with ingesting Tide Pods.  Learn more about this episode of Let's Talk Hemp at www.letstalkhemp.com. Got questions for future episodes? Email us at the422@letstalkhemp.com. LTH422 intro and outro music powered by MoTron and the #HempCaster Guitar @ Hole in the Sky Music.

Show description/summary:1) Epidemiology and Prognosis of Mild Traumatic Brain Injury in Returning Soldiers: A Cohort Study2) What's Trending: Alemtuzumab treatment and multiple sclerosisThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the April 18, 2017 issue of Neurology. In the first segment, Dr. Michael Jaffee talks with Dr. Karen Schwab about her paper on mild traumatic brain injury in returning soldiers. For our “What's Trending” feature of the week, Dr. Mark Keegan talks with Dr. Gavin Giovannoni about his paper on alemtuzumab treatment and multiple sclerosis. For more information on traumatic brain injury services for active duty military and veterans, please visit the Defense and Veterans Brain Injury Center website at http://dvbic.dcoe.mil. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Jaffee serves on the scientific advisory board for Neurohabitation, Inc., and has received research support from the Florida State Department of Elderly Affairs.Dr. Schwab receives research support from Congressionally Directed Medical Research Programs (Grant #W81XWH-08-2-0105).Dr. Keegan serves on the editorial board for Multiple Sclerosis and Related Disorders; served as eMedicine Chief Editor from 2009 to 2015; receives publishing royalties for Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases: Case-Based Learning (Cambridge University Press 2016); consults for Novartis, Bristol Meyers Squibb, and Bionest; and received research support from Biogen for the ARISE study.Dr. Giovannoni consulted and served on scientific advisory boards for Biogen-Idec, Fiveprime, Genzyme, GW Pharma, Ironwood, Merck-Serono, Novartis, Roche, Sanofi-Aventis, Synthon BV, Teva, Vertex Pharmaceuticals, Abbvie, and Canbex; receives speaker honoraria from Biogen-Idec, Genzyme, GW Pharma, Merck-Serono, Novartis, Roche, and Teva Pharmaceuticals; serves as an editor for Multiple Sclerosis and Related Disorders; served on speaker's bureaus for Novartis and Teva; and received research support from Genzyme and Merck.

GW Pharma has cleared another hurdle in gaining FDA approval for its drug called Epidiolex, boosting stock value for the British drug maker.

Today in FirstWord:

1) Neurology® Neuroimmunology & Neuroinflammation: Vasculitis neuropathy following exposure to minocycline 2) e-Pearl topic: Primary progressive aphasia3) Topic of the month: Neurology Today story about a wearable EEG device This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Chafic Karam about his Neurology: Neuroimmunology & Neuroinflammation paper on vasculitis neuropathy following exposure to minocycline. Dr. Ilena George is reading our e-Pearl of the week about primary progressive aphasia. Dr. Ted Burns interviews Dr. Jacqueline French about a Neurology Today story on the topic of a wearable EEG device. DISCLOSURES: Dr. Ted Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Karam serves as Deputy Editor for Neurology Write Click; served on the editorial team for the Neurology® Resident and Fellow Section; received speaker honoraria from Nufactor, Inc.; received consulting honoraria from Lundbeck Inc.Dr. George serves on the editorial team for the Neurology Resident and Fellow Section.Dr. French is a consultant for Acorda Therapeutics, Anavex, Brabant Pharma, Bio-Pharm Solutions, Eisai Inc., GlaxoSmithKline, GW Pharma, Impax, Johnson and Johnson, Marinus Pharmaceuticals, Inc., Neusentis, Novartis, Pfizer Inc, Sage, Sunovion Pharmaceuticals Inc., SK Life Sciences, Supernus, Takeda, UCB Pharma, Upsher-Smith Laboratories, Inc., Ultragenyx, Vertex, Zogenix, and Zynerba, all consulting was on behalf of the Epilepsy Study Consortium, and fees are paid to the consortium and New York University receives salary support from the consortium; serves as Associate Editor for Epilepsia; serves as an Editorial board member for Lancet Neurology, Neurology Today and Epilepsy Currents; research support from Acorda Therapeutics, Alexza, LCGH, Eisai Inc., Lundbeck Inc, Pfizer Inc, SK Life Sciences, UCB Pharma, Upsher-Smith Laboratories, Vertex, NIH, and the Epilepsy Foundation.NO CME WILL BE OFFERED THIS WEEK.